BioSpace News Archive

Biotech Bay

Guardant Health to Participate in Upcoming May 2024 Investor Conferences

Guardant Health, Inc., a leading precision oncology company, announced the company will participate in the following investor conferences.

May 7, 2024
·
1 min read
Deals

Baxter Declares Quarterly Dividend - May 7, 2024

Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced that its Board of Directors has declared a quarterly cash dividend of $0.29 per share of common stock.

May 7, 2024
·
1 min read
Bio NC

Precision BioSciences Announces Receipt of FDA Fast Track Designation for ECUR-506, iECURE’s Program for the Treatment of Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency

Precision BioSciences, Inc. (Nasdaq: DTIL) today announced that its partner iECURE has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for ECUR-506.

May 7, 2024
·
11 min read
Drug Development

Mirum Announces Publication of Phase 3 MARCH Data in The Lancet Demonstrating Benefits of LIVMARLI (maralixibat) in patients with PFIC

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that data from the Phase 3 MARCH-PFIC study evaluating LIVMARLI® (maralixibat) oral solution in patients with PFIC was published in The Lancet Gastroenterology and Hepatology.

May 7, 2024
·
8 min read
Biotech Bay

Turn Biotechnologies Discussed Emerging Therapies at Aesthetic Plastic Surgery Society Meeting

Turn Biotechnologies, a developer of novel mRNA medicines and enabling technologies, presented its breakthrough research and therapies to treat age-related diseases to members of the American Society for Aesthetic Plastic Surgery, known as The Aesthetic Society.

May 7, 2024
·
2 min read
Drug Development

NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS Patients

NeuroSense Therapeutics Ltd. announces new analyses from its Phase 2b PARADIGM clinical trial, demonstrated a statistically significant slowing of disease progression in high-risk ALS patients treated with PrimeC by 43% (p=0.02) as compared to placebo in the pre-specified per protocol (PP) population analysis after 6 months of treatment.

May 7, 2024
·
9 min read
NervGen Files Management Information Circular and Announces Board of Directors Transition

NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage

May 7, 2024
·
5 min read
Lone Star Bio

Moleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability with Additional Interim Subject Data

Moleculin Biotech, Inc. announced the presentation of positive interim data for Annamycin from its ongoing acute myeloid leukemia clinical development program.

May 7, 2024
·
9 min read
Drug Development

Inmagene Announces Completion of Enrollment in Phase 2a Trial of IMG-007, a Nondepleting and Half-life Extended Anti-OX40 Monoclonal Antibody, in Patients with Alopecia Areata

Inmagene Biopharmaceuticals today announced that the Company completed target enrollment in its Phase 2a trial evaluating IMG-007 in adult patients with AA.

May 7, 2024
·
3 min read
Biotech Beach

Clinical Study Highlights Improvements to Gut Microbiome and Autism Spectrum Disorder Symptoms with Use of Custom Probiotics

Researchers with Sun Genomics and Arizona State University have discovered that probiotic supplementation may improve symptoms in people with autism spectrum disorder.

May 7, 2024
·
5 min read